一种安全和广泛的SARS-CoV-2mRNA疫苗,具有用于现场表达的新输送系统
Weiyi Yu1, Xianying Chen2, Qiubing Chen3
1State Key Laboratory of Virology and Biosafety, RNA Institute, College of Life Sciences and Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, 430072, China.
Virologica Sinica
|September 6, 2025
概括
一种新的脂质纳米粒子 (LNP) 疫苗系统,WNP,显示出强大的免疫反应和针对SARS-CoV-2的mRNA疫苗开发的安全性. 这种可适应的平台显示了未来疫情准备的潜力.
科学领域:
- 疫苗学
- 免疫学
- 生物技术
背景情况:
- 由SARS-CoV-2引起的COVID-19大流行需要快速开发安全有效的mRNA疫苗.
- 现有的疫苗平台在适应性,工业化和安全性方面面临挑战.
研究的目的:
- 开发和评估一种新的脂质纳米粒子 (LNP) 系统,即mRNA疫苗的WNP.
- 使用突变策略设计一种广泛有效的SARS-CoV-2抗原.
- 评估基于WNP的疫苗的免疫性和安全性.
主要方法:
- 在现场mRNA表达的WNP脂质纳米粒子系统的开发.
- 包含五个关键突变 (K417T,L452R,T478K,E484K,N501Y) 的受体结合域 (RBD) 抗原的设计.
- 在临床前模型中评估幽默和细胞免疫反应和保护作用.
主要成果:
- WNP 系统表现出在位表达与减少的促炎性肝因子,增强安全性.
- 设计的RBD抗原产生了强大的体内免疫力,
- 在WNP疫苗中观察到更强的细胞免疫反应和保护作用.
结论:
- 该系统为针对SARS-CoV-2的mRNA疫苗开发提供了一个安全有效的平台.
- 这种可适应的疫苗技术有望迅速应对新出现的病毒威胁.
- 可以将WNP技术扩展到针对其他病原体的疫苗.
相关概念视频
01:23Vaccine Production
144
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
144
01:21Vaccines
98
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
98